Clinical trials: SCHIZOPHRENIA 1 (Disorder)
Schizophrenia
Prospective Studies of the Pathogenesis of Schizophrenia
The purpose of this study is to use structural and functional magnetic resonance imaging (MRI) to study children at high risk for schizophrenia.
- Trial name
- NCT00877552
- Where
- United States
- Volunteers
- 598 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Heart Diseases, Heart; Functional Disturbance
The Protein Disrupted in Schizophrenia 1 (DISC1) as a Novel Biomarker for Cardiac Disease
To study the association between DISC1 RNA expression levels and cardiac function in patients with schizophrenia.
- Conditions
- Heart Diseases, Heart; Functional Disturbance, Schizophrenia
- Trial name
- NCT06304233
- Testing
- Echocardiography, Cardiac Magnetic Resonance Imaging, Electrocardiography
- Where
- 2 sites in Norway
- Volunteers
- 120 people
- Sponsor
- Norwegian University of Science and Technology
Schizophrenia
Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo
This study is being carried out to see if quetiapine (Seroquel) is effective in preventing patients from a schizophrenic relapse when studied for a long time (1 year) and if so, how it compares with non-active treatment.
- Trial name
- NCT00228462
- Testing
- Seroquel (quetiapine)
- Where
- 5 sites in Bulgaria, Poland
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Schizophrenia
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing
- Trial name
- NCT04787302
- Testing
- CVL-231
- Where
- 2 sites in United States, Belgium
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC
Schizophrenia or Schizoaffective Disorder
Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body, safety and tolerability of AMG 581 in healthy participants and subjects with schizophrenia.
- Trial name
- FIH (NCT02567370)
- Testing
- AMG 581
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amgen
Schizophrenia, Major Depressive Disorder
Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
This study will assess the helpfulness of the integrated call center in optimizing use of the Digital Medicine System in adult subjects with Schizophrenia, Major Depressive Disorder, or Bipolar Disorder taking oral aripiprazole.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT02722967
- Testing
- Aripiprazole + IEM (Ingestible Event Marker)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
SCHIZOPHRENIA 1 (Disorder), Hospitalized Adult Patients
Feasibility, Acceptability, and Effectiveness of a Hatha Yoga-in Patients Hospitalized for Schizophrenia
The current study aims to examine the feasibility, acceptability, and preliminary effectiveness of a Hatha yoga-based group intervention on reminiscence functions and mindfulness in a sample of patients hospitalized for…
- Trial name
- NCT07454200
- Testing
- Intervention Arm: Hatha Yoga
- Volunteers
- 36 people
- Sponsor
- The Hashemite University
Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature
Building a Computational Model of Auditory Hallucinations
Some people hear voices or sounds that other people cannot hear; these are called auditory hallucinations. The study aims to understand what is happening in the brain when this occurs and will use brain scans to learn more.
- Conditions
- Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature, Psychosis, SCHIZOPHRENIA 1 (Disorder)
- Trial name
- CLARITY WP1 (NCT07820553)
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- King's College London
Schizophrenia, Schizoaffective Disorder
CLOZAPINE Response in Biotype-1
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
- Trial name
- NCT04580134
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 524 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen.
- Trial name
- NCT01348100
- Testing
- Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Long-Term Exercise Training Therapy Versus Usual Care in Patients With Schizophrenia
Patients with schizophrenia have disabling symptoms and cognitive deficits that limit motivation, drive, social- and occupational performance, quality of life and self-efficacy.
- Trial name
- LEXUS (NCT02743143)
- Testing
- Exercise therapy, Follow-up care as usual
- Where
- Norway
- Volunteers
- 48 people
- Sponsor
- St. Olavs Hospital
Schizophrenic Disorders
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one…
- Trial name
- RECOVER (NCT00600756)
- Testing
- Quetiapine XR, Risperidone
- Where
- 116 sites in Belgium, Brazil and 12 more
- Volunteers
- 798 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics
The purpose of this study is to assess the effectiveness, safety and tolerability of flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully treated by oral antipsychotics and with acute…
- Trial name
- NCT01685931
- Testing
- Paliperidone Palmitate
- Where
- 17 sites in China
- Volunteers
- 617 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Bipolar 1 Disorder, Schizophrenia
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are currently on treatment with oral aripiprazole.
- Conditions
- Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Disorders
- Trial name
- NCT02050854
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Lithium Drug-Drug Interaction Study With Lurasidone HCl
The purpose of this study is to evaluate the drug-drug interaction effect between Lithium and Lurasidone HCl.
- Trial name
- NCT01074073
- Testing
- Lurasidone HCl
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
- Trial name
- NCT02320032
- Testing
- Aripiprazole Lauroxil
- Where
- 16 sites in United States
- Volunteers
- 140 people
- Sponsor
- Alkermes, Inc.
SCHIZOPHRENIA 1 (Disorder), Simulation Based Learning
Simulation-Based Schizophrenia Training in Nursing Education
This study aims to examine the effect of a schizophrenia scenario-based simulation on nursing students' knowledge, empathy, and caregiving competence. The study uses a single-group pre-test/post-test (quasi-experimental) design.
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Simulation Based Learning, Nursing Students
- Trial name
- NCT07757750
- Testing
- Simulation
- Where
- Turkey (Türkiye)
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Medipol University
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
SCHIZOPHRENIA 1 (Disorder), Metabolic Abnormalities
Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.
The aim of the present study is to evaluate the effectiveness of the addition of the postbiotic Pediococcus acidilactici (pA1c®HI) on amelioration of metabolic disturbances in patients with (FEP) or (SSD) treated with…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Metabolic Abnormalities, Postbiotic Supplement
- Trial name
- GLUCOPSICO (NCT07371325)
- Testing
- Pediococcus acidilactici, pA1c®HI postbiotic supplementation taking participants, Atypical antipsychotics (AAP)
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Manuel Jesús Cuesta Zurita
Schizophrenia
Comparative Bioavailability of Risperidone.
This is an Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany).
- Trial name
- NCT05179525
- Testing
- Risperidone ISM® 100 mg, Risperdal 4mg Tablet
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Rovi Pharmaceuticals Laboratories